RAD51C and ovarian carcinoma: We aimed to perform a comprehensive molecular analysis of a large cohort of patients with RAD51C/D untreated primary breast cancer and ovarian cancer to describe the prevalence of HRD by different biomarkers and investigate the role of the germline alterations in tumorigenesis.